BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 11418367)

  • 21. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
    Lange BJ; Blatt J; Sather HN; Meadows AT
    Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881.
    Hutchinson RJ; Gaynon PS; Sather H; Bertolone SJ; Cooper HA; Tannous R; Wells LM; Heerema NA; Sailer S; Trigg ME;
    J Clin Oncol; 2003 May; 21(9):1790-7. PubMed ID: 12721256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Analysis of therapeutic effectiveness in 158 childhood acute lymphoblastic leukemia patients treated with ALL-XH-99 protocol].
    Gu LJ; Li J; Xue HL; Tang JY; Chen J; Zhao HJ; Chen J; Ye H; Wang YP; Pan C
    Zhonghua Xue Ye Xue Za Zhi; 2004 Jan; 25(1):1-4. PubMed ID: 14990066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Results of the CCLSG high risk ALL 874 protocol in childhood acute lymphoblastic leukemia. Children's Cancer and Leukemia Study Group].
    Kawai S; Fujimoto T; Zha Z; Asami K; Oka T; Kaneko Y; Takaue Y; Ninomiya T; Nishikawa K; Tsuchiya T
    Rinsho Ketsueki; 1993 Feb; 34(2):128-36. PubMed ID: 8492409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
    Ribera JM; Oriol A; Sanz MA; Tormo M; Fernández-Abellán P; del Potro E; Abella E; Bueno J; Parody R; Bastida P; Grande C; Heras I; Bethencourt C; Feliu E; Ortega JJ
    J Clin Oncol; 2008 Apr; 26(11):1843-9. PubMed ID: 18398150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial.
    Hunault M; Truchan-Graczyk M; Caillot D; Harousseau JL; Bologna S; Himberlin C; Guyotat D; Berthou C; Casassus P; Baranger L; Béné MC; Ifrah N; Gyan E;
    Haematologica; 2007 Dec; 92(12):1623-30. PubMed ID: 18055985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of standard risk acute lymphoblastic leukemia in children with the Tokyo Children Cancer Study Group (TCCSG) L84-11 protocol in Japan.
    Tsukada M; Komiyama A; Nakazawa S; Tsuchida M; Nishihira H; Shitara T; Ohira M; Tsunematsu Y; Yamamoto K; Hoshi Y
    Int J Hematol; 1993 Jan; 57(1):1-7. PubMed ID: 8477058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99.
    Brandalise SR; Pinheiro VR; Aguiar SS; Matsuda EI; Otubo R; Yunes JA; Pereira WV; Carvalho EG; Cristofani LM; Souza MS; Lee ML; Dobbin JA; Pombo-de-Oliveira MS; Lopes LF; Melnikoff KN; Brunetto AL; Tone LG; Scrideli CA; Morais VL; Viana MB
    J Clin Oncol; 2010 Apr; 28(11):1911-8. PubMed ID: 20212252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical trial of protocol-AL851 for children with high-risk acute lymphoblastic leukemia. Kyushu Yamaguchi Children's Cancer Study Group (KYCCSG)].
    Matsuzaki A; Ishii E; Ueda K; Yanai F; Nibu K; Take H; Koga H; Miyazaki S; Inoue T; Miyake K
    Rinsho Ketsueki; 1994 Sep; 35(9):862-70. PubMed ID: 7967055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment outcome of adolescents with acute lymphoblastic leukemia.
    Irken G; Oren H; Gülen H; Duman M; Uçar C; Atabay B; Yilmaz S; Uysal K; Cevik N
    Ann Hematol; 2002 Nov; 81(11):641-5. PubMed ID: 12454702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Could intensified treatment in childhood acute lymphoblastic leukemia improve outcome independently of risk factors?
    Tzortzatou-Stathopoulou F; Moschovi MA; Papadopoulou AL; Barbounaki IG; Lambrou GI; Balafouta M; Syriopoulou V
    Eur J Haematol; 2005 Nov; 75(5):361-9. PubMed ID: 16191084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
    Janka-Schaub GE; Harms DO; den Boer ML; Veerman AJ; Pieters R
    Klin Padiatr; 1999; 211(4):233-8. PubMed ID: 10472556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial.
    Ribera JM; Ortega JJ; Oriol A; Bastida P; Calvo C; Pérez-Hurtado JM; González-Valentín ME; Martín-Reina V; Molinés A; Ortega-Rivas F; Moreno MJ; Rivas C; Egurbide I; Heras I; Poderós C; Martínez-Revuelta E; Guinea JM; del Potro E; Deben G
    J Clin Oncol; 2007 Jan; 25(1):16-24. PubMed ID: 17194902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improvement in treatment of childhood acute lymphoblastic leukemia: a 10-year study by the Children's Cancer and Leukemia Study Group.
    Koizumi S; Fujimoto T
    Int J Hematol; 1994 Feb; 59(2):99-112. PubMed ID: 8018909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of standard-risk acute lymphoblastic leukemia in children: the results of protocol AL841 from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
    Matsuzaki A; Okamura J; Ishii E; Ikuno Y; Koga H; Eguchi H; Yanai F; Inada H; Nibu K; Hara T; Take H; Miyazaki S; Tasaka H
    Pediatr Hematol Oncol; 1999; 16(3):187-99. PubMed ID: 10326217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.
    Nachman JB; Sather HN; Sensel MG; Trigg ME; Cherlow JM; Lukens JN; Wolff L; Uckun FM; Gaynon PS
    N Engl J Med; 1998 Jun; 338(23):1663-71. PubMed ID: 9614257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients].
    Jin FY; Zou DH; Wang GR; Xu Y; Feng SZ; Zhao YZ; Han MZ; Yan WW; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):645-8. PubMed ID: 16620547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.
    Tolar J; Bostrom BC; La MK; Sather HN
    Pediatr Blood Cancer; 2005 Jul; 45(1):5-9. PubMed ID: 15481062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
    Sancho JM; Ribera JM; Oriol A; Hernandez-Rivas JM; Rivas C; Bethencourt C; Parody R; Deben G; Bello JL; Feliu E;
    Cancer; 2006 Jun; 106(12):2540-6. PubMed ID: 16700036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.